Laura Deming is a notable investor and partner at The Longevity Fund with a focus on biotechnology and longevity research, including biomarkers.Her interests lie in innovative biotechnologies. She has supported companies like Unity Biotechnology, which addresses aging-related diseases, and Erasca, specializing in precision cancer therapeutics. Additionally, she's invested in Prelude Therapeutics for cancer drug development and Navitor Pharmaceuticals exploring mitochondrial metabolism. Nucleai, a company combining AI and pathology for enhanced cancer diagnostics, also falls within her investment spectrum.